Disease landscape

Triple-Negative Breast Cancer clinical trials

Get alerts when Triple-Negative Breast Cancer trials change

426 active trials 244 recruiting 47 Phase 3 270 sponsors 55 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days showing 39 of 55 changes on 19 trials

2026-08-13
Trial status changed: Recruiting → Withdrawn
Trial withdrawn: no patients were able to be enrolled
Enrollment reduced: 30 → 0 participants
Primary completion pushed: 2026-06-30 → 2026-08-10
Completion pushed: 2026-06-30 → 2026-08-10
NCT06610097 TNBC Gut Microbiota During Neoadjuvant Treatment · Scripps Health
2026-08-05
Primary completion pushed: 2026-07 → 2027-09
Completion pushed: 2026-07 → 2027-09
Trial arms changed: 9 → 10
NCT06084481 Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With… · AbbVie · Phase 1
2026-08-21
Primary completion pushed: 2026-09 → 2027-08
Completion pushed: 2027-03 → 2027-08
NCT06027268 Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic… · Wake Forest University Health Sciences · Phase 2
2026-08-14
Primary completion pushed: 2026-10-01 → 2027-06-01
Enrolling by invitation only
NCT06910072 Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and… · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 2/3
2026-08-18
Primary completion pushed: 2028-08 → 2030-08
Completion pushed: 2028-08 → 2030-08
NCT04861077 Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission… · University of Alabama at Birmingham · Early Phase 1
2026-08-13
Primary completion pushed: 2026-07 → 2026-11
NCT04768426 Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early… · Stanford University · Phase 2
2026-08-22
Primary endpoint(s) modified
Recruitment opened
Enrollment increased: 56 → 299 participants
Trial sites expanded: 0 → 3 locations
Primary completion moved earlier: 2028-08 → 2027-08
Trial arms changed: 2 → 3
NCT07623369 A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors · Huahui Health · Phase 1
2026-08-19
Enrollment reduced: 120 → 65 participants
Trial completed
Primary completion moved earlier: 2026-06-30 → 2026-04-20
Completion moved earlier: 2026-12-31 → 2026-05-29
NCT06685796 A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced… · BeBetter Med Inc · Phase 2
2026-08-07
Enrollment reduced: 450 → 165 participants
Enrollment closed, study ongoing
Trial sites reduced: 41 → 36 locations
NCT05581004 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single… · Genentech, Inc. · Phase 1
2026-08-27
Enrollment closed, study ongoing
NCT06577987 Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies · Circle Pharma · Phase 1
2026-08-09
Sponsor changed: ITM Oncologics GmbH → Lumara Bio Oncologics GmbH
NCT05706129 A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452… · Lumara Bio Oncologics GmbH · Phase 1/2
2026-08-25
Enrollment reopened
NCT06084481 Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With… · AbbVie · Phase 1
2026-08-19
Recruitment opened
NCT07544056 A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic… · BeBetter Med Inc · Phase 2/3
2026-08-19
Recruitment opened
NCT07545122 A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific… · Context Therapeutics Inc. · Phase 1
2026-07-30
Enrollment closed, study ongoing
NCT06419621 PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally… · Biotheus Inc. · Phase 3
2026-08-14
Enrollment closed, study ongoing
NCT06399757 A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors · Apollo Therapeutics Ltd · Phase 1/2
2026-08-09
Sponsor changed: West German Study Group → Women's Cancer Study Group GmbH
NCT06081244 NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk… · West German Study Group · Phase 3
2026-08-06
Sponsor changed: West German Study Group → Women's Cancer Study Group GmbH
NCT07178730 NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in… · Women's Cancer Study Group GmbH · Phase 3
2026-08-25
Recruitment opened
NCT07743190 A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant… · Medical University of South Carolina · Phase 2
2026-08-09
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University → Second Affiliated Hospital, Zhejiang University, School of Medicine
NCT07457359 Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer · Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 2

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-26 NCT07786428 Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC University of Texas Southwestern Medical Center new Phase 2
2026-08-13 NCT07762703 Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic… BreakBio Corp new Phase 1/2
2026-08-04 NCT07743723 A Study of IOV-5001 in Adults With Advanced Solid Tumors Iovance Biotherapeutics new Phase 1/2
2026-07-28 NCT07730125 Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory… CoRegen, Inc. new Phase 1/2
2026-07-23 NCT07723469 Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing… SURGE Therapeutics new Phase 3
2026-07-23 NCT07721259 A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer… University of Washington new Phase 2
2026-07-20 NCT07714382 Survival Outcomes of Residual Disease in Triple-Negative Breast Cancer Sohag University new
2026-07-15 NCT07705334 A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic… SHY Therapeutics new Phase 1
2026-07-07 NCT07687446 Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative… Assistance Publique - Hôpitaux de Paris new
2026-07-02 NCT07681297 Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors… National University Hospital, Singapore new Phase 1/2

Active trials by phase

Early Phase 1
10
Phase 1
75
Phase 1/2
62
Phase 2
151
Phase 2/3
3
Phase 3
44
Phase 4
3
Not charted: 78 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 426

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT06920810 Viscum Album for TNBC on Adjuvant Pembrolizumab Ilsan Cha hospital Recruiting 2025-04-10
NCT04790305 Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative… Fudan University Recruiting 2024-06-27
NCT05843292 Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy… Shanghai Jiao Tong University School of Medicine Not Yet Recruiting 2023-06-06
Phase 3
NCT06393374 Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not… Merck Sharp & Dohme LLC Recruiting 2026-08-21
NCT06081244 NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk… West German Study Group Recruiting 2026-08-03
NCT06606730 Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early… UNICANCER Recruiting 2026-07-23
NCT05633654 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's… Gilead Sciences Recruiting 2026-07-15
NCT06279364 A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable… Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recruiting 2026-05-08
NCT07533123 A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With… Jiangsu Alphamab Biopharmaceuticals Co., Ltd Recruiting 2026-04-16
NCT05806060 Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally… Fudan University Recruiting 2026-03-25
NCT06767527 AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally… Akeso Recruiting 2026-03-16
NCT06627712 SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC West China Hospital Recruiting 2026-01-30
NCT05909332 Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant… Fudan University Recruiting 2026-01-21
NCT07111832 A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. Recruiting 2025-12-18
NCT04722978 Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic… Sun Yat-Sen University Cancer Center Recruiting 2025-12-17
NCT06732323 A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative… Qilu Pharmaceutical Co., Ltd. Recruiting 2025-09-23
NCT05862064 A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined… Fudan University Recruiting 2025-07-16
NCT03671044 A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in… Jina Pharmaceuticals Inc. Recruiting 2025-03-21
NCT06533384 PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC Guangdong Provincial People's Hospital Recruiting 2024-11-04
NCT05999149 A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as… Fudan University Recruiting 2024-02-21
NCT05760378 Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of… Fudan University Recruiting 2024-02-06
NCT05954442 Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast… Fudan University Recruiting 2024-01-16
NCT07729956 A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1… Sichuan Baili Pharmaceutical Co., Ltd. Not Yet Recruiting 2026-08-26
NCT07760844 An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without… Fudan University Not Yet Recruiting 2026-08-12
NCT07178730 NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in… Women's Cancer Study Group GmbH Not Yet Recruiting 2026-08-05
See all 426 active Triple-Negative Breast Cancer trials with filters →

Top sponsors by active trials in this area

Fudan University (34) · Memorial Sloan Kettering Cancer Center (8) · Tianjin Medical University Cancer Institute and Hospital (7) · Gilead Sciences (6) · H. Lee Moffitt Cancer Center and Research Institute (6) · M.D. Anderson Cancer Center (6) · Institut Curie (5) · Massachusetts General Hospital (5) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (4) · Harbin Medical University (4)

Get alerts when Triple-Negative Breast Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free